HighTide Therapeutics Inc

HighTide Therapeutics Inc an investment holding company engages in the discovery research and development and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs Its lead product candidate is HTD1801 a gutliver antiinflammatory metabolic modulator that targets metabolic dysfunctionassociated steatohepatitis type 2 diabetes mellitus severe hypertriglyceridemia primary sclerosing cholangitis and primary biliary cholangitis The company is also developing HTD4010 a polypeptide drug for the treatment of alcoholic hepatitis HTD1804 to treat obesity HTD1805 a multifunctional small molecule drug for the treatment of metabolic diseases and HTD2802 for the treatment of inflammatory bowel disease HighTide Therapeutics Inc was founded in 2011 and is headquartered in Shenzhen China